CorMedix Inc. Abstracts Accepted for Presentation at American Society of Nephrology Kidney Week 2015

BEDMINSTER, NJ / ACCESSWIRE / August 31, 2015 / CorMedix Inc. (NYSE MKT: CRMD), a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of cardiorenal and infectious diseases, today announced that the American Society of Nephrology has accepted two abstracts for poster presentation at Kidney Week 2015. The data to be presented highlight the economic burden of central venous catheter complications to the healthcare system.

“Infection and thrombosis are two complications from long-term catheter use that can lead to significant healthcare costs,” said Antony Pfaffle, M.D., Chief Scientific Officer and Co-Founder, CorMedix. “This is an important issue and we are pleased that this data was recognized by the American Society of Nephrology for presentation to its members and healthcare professionals at this key meeting.”

The abstracts submitted and selected for poster presentation include:

Economic Burden to Dialysis Providers of Central Venous Catheter (CVC)-Related Blood Stream Infections (BSI) and Occlusions Among Incident Hemodialysis (HD) Patients

Session Title: Hemodialysis Vascular Access: From Bench to Bedside
Session Date, Time: Thursday, November 5, 2015, 10:00 AM – 12:00 PM
Abstract Poster Number: TH-PO796

Economic Burden to Medicare of Central Venous Catheter (CVC)-Related Blood Stream Infections (BSI) and Occlusions Among Incident Hemodialysis (HD) Patients

Session Title: Hemodialysis Vascular Access: From Bench to Bedside
Session Date, Time: Thursday, November 5, 2015, 10:00 AM – 12:00 PM
Abstract Poster Number: TH-PO821

About CorMedix Inc.

CorMedix Inc. is a commercial-stage pharmaceutical company that seeks to in-license, develop and commercialize therapeutic products for the prevention and treatment of cardiorenal and infectious diseases. CorMedix’s first commercial product in Europe is Neutrolin(R), a catheter lock solution for the prevention of catheter related bloodstream infections and maintenance of catheter patency in tunneled, cuffed, central venous catheters used for vascular access in hemodialysis patients, in addition to oncology patients, critical care patients, and patients receiving total parenteral nutrition, IV hydration and/or IV medications. Plans are in progress to expand commercial distribution into the United States, Asia, the Middle East, South America and Africa upon appropriate regulatory approval. For more information, visit www.cormedix.com.

Contact:

Investors:
CorMedix Inc.
Randy Milby
(908) 517-9489

Media:
Mike Beyer
Sam Brown Inc.
(312) 961-2502
mikebeyer@sambrown.com

SOURCE: CorMedix Inc.

ReleaseID: 431610